Cover Image
市場調查報告書

注射型藥物輸送的全球市場:市場規模,佔有率,發展,成長,需求預測

Global Injectable Drug Delivery Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 536397
出版日期 內容資訊 英文 190 Pages
商品交期: 請詢問到貨日
價格
Back to Top
注射型藥物輸送的全球市場:市場規模,佔有率,發展,成長,需求預測 Global Injectable Drug Delivery Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023
出版日期: 2017年07月26日 內容資訊: 英文 190 Pages
簡介

本報告提供注射型藥物輸送的全球市場調查,整體市場趨勢,各類型、治療的適用、利用模式、終端用戶、地區的詳細趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會、課題分析,競爭情形,主要企業簡介等系統性資訊。

第1章 簡介

第2章 市場概要

  • 注射型藥物輸送的全球市場:發展和變遷
  • 市場定義、範圍
  • 產業結構
  • 法律規範
  • 市場分析
    • 調查結果
    • 市場機會
    • 主要企業
    • 策略
  • 預測分析
  • 策略分析
    • 投資 vs 引進模式
    • 全方位的分析
    • 波特的五力分析
    • 翹翹板理論
    • 客戶分析、購買標準
  • 競爭分析
    • 策略分析
    • 市場佔有率分析
  • 策略建議
    • 投資機會:各地區
    • 新用途的市場機會
    • 最快成長市場上投資機會

第3章 市場決策要素

  • 推動因素
  • 阻礙因素
  • 機會
  • 課題

第4章 市場區隔

  • 注射型藥物輸送市場:各類型
    • 注射型藥物輸送設備
    • 注射型藥物輸送製劑
  • 注射型藥物輸送市場:各製劑
    • 安瓿製劑
    • 瓶裝製劑
    • 濾芯製劑
    • 管瓶製劑
  • 注射型藥物輸送市場:各治療的適用
    • 免疫疾病
    • 內分泌疾病
    • 癌症
    • 罕見疾病
    • 其他
  • 注射型藥物輸送市場:各利用模式
    • 根治治療
    • 免疫治療
    • 其他
  • 注射型藥物輸送市場:各終端用戶
    • 醫院
    • 居家照護
    • 其他(研究機關,臨床診斷實驗室)

第5章 競爭情形

  • 主要策略
    • 合併、收購
    • 合資企業
    • 新產品的投入
    • 夥伴關係

第6章 地區分析

  • 決策依據的資料庫
  • 產業間比較分析
  • 市場機會的矩陣
  • 注射型藥物輸送的全球市場:各地區
    • 北美
      • 產業分析
      • 各國
    • 歐洲
      • 產業分析
      • 各國
    • 亞太地區
      • 產業分析
      • 各國
    • 其他地區
      • 產業分析
      • 各國

第7章 企業簡介

目錄
Product Code: HPH-6530817

Injectable drug delivery is used for direct introduction of a pharmaceutical drug in body of the patient with the help of a delivery device. The global inject able drug delivery market is expected to rise at a CAGR of 12% during the forecast period 2016-2023. Growth in pharmaceutical and biotechnology industry is contributing to the growth of the global inject able drug delivery market. However, infection associated with needle stick injury is the factor restraining the growth of the global inject able drug delivery market during the forecast period.

Geographically, North America accounted for the largest market share in terms of revenue for inject able drug delivery market in 2016 and the region is expected to dominate the market during the forecast period followed by Europe. The dominance of the region is attributed to technologically advanced healthcare facilities in the countries of the region. However, Asia Pacific is expected to be the fastest growing region for inject able drug delivery market during the forecast period. The highest growth in the region is observed due to enhancing healthcare infrastructure and prevalence of chronic diseases in the region.

The growth in global inject able drug delivery market is also influenced by the presence of major players such as Baxter International (U.S.), Schott AG (Germany), Terumo Corporation (U.S.), Hospira Inc. (U.S.), Sanofi SA (France) etc. The market players adopt some crucial strategies such as product launches, partnerships, mergers & acquisitions etc.to gain competitive advantage.

Global inject able drug delivery market report covers segmentation analysis of type, formulation, therapeutic application, usage pattern and end users. Report further covers segmentsof type which includes device and formulations. Device is expected to dominate the segment during the forecast period owing to rising usage in management and control of various disorders at primary level. Formulation packaging in inject able drug delivery is divided as ampoules, bottles, cartridges and vials. Moreover, therapeutic applications of inject able drug delivery include auto immune diseases, hormonal disorders, oncology, orphan diseases and other applications. Oncology is expected to dominate the segment during the forecast period owing to increasing application of inject able drug delivery in diagnosis and treatment of cancer and diabetes. Furthermore, usage pattern segment of inject able drug delivery can be sub divided as curative care, immunization and others. Also, end users of inject able drug delivery include hospitals, homecare and others (Research institutes, clinical, diagnostic laboratories). Homecare segment is expected to dominate the segment during the forecast period owing to increasing demand for self-injection devices which provides easy administration of drugs at home without medical assistance.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. INJECTABLE DRUG DELIVERY MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATORY FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTERS 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. KEY STRATEGIES & ANALYSIS
    • 2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. INCREASED DEMAND FOR SELF INJECTION DEVICES
    • 3.1.2. RISING PREVALENCE OF CHRONIC DISEASES
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN MEDICAL INDUSTRY
    • 3.1.4. NEW PRODUCT LAUNCHES
    • 3.1.5. GROWTH IN BIOLOGICS MARKET
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. INFECTIONS ASSOCIATED WITH NEEDLLESTICK INJURIES
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. INCREASING DEMAND FOR BIOSIMILAR AND GENERIC INJECTABLES
    • 3.3.2. INCREASING APPLICATIONS OF CONTRACEPTIVE INJECTABLES
  • 3.4. MARKET CHALLENGES
    • 3.4.1. PREFERENCE FOR OTHER MODES OF DRUG DELIVERY

4. MARKET SEGMENTATION

    • 4.1.1. INJECTABLE DRUG DELIVERY MARKET BY TYPE
    • 4.1.2. MARKET DEFINITION AND SCOPE
    • 4.1.3. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.4. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.5. OPPORTUNITY MATRIX
    • 4.1.6. MARKET SEGMENTATION
      • 4.1.6.1. GLOBAL DEVICES MARKET
        • 4.1.6.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.6.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.6.1.3. TOP PLAYERS & KEY PRODUCTS
        • 4.1.6.1.4. KEY CONCLUSIONS
      • 4.1.6.2. GLOBAL FORMULATIONS MARKET
        • 4.1.6.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.6.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.6.2.3. TOP PLAYERS & KEY PRODUCTS
        • 4.1.6.2.4. KEY CONCLUSIONS
  • 4.2. INJECTABLE DRUG DELIVERYMARKET BY FORMULATION
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION
      • 4.2.5.1. GLOBAL AMPULES MARKET
        • 4.2.5.1.1. APPLICATION
        • 4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.1.5. KEY CONCLUSIONS
      • 4.2.5.2. GLOBAL BOTTLES MARKET
        • 4.2.5.2.1. APPLICATION
        • 4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.2.5. KEY CONCLUSIONS
      • 4.2.5.3. GLOBAL CARTRIDGES MARKET
        • 4.2.5.3.1. APPLICATION
        • 4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.3.5. KEY CONCLUSIONS
      • 4.2.5.4. GLOBAL VIALS MARKET
        • 4.2.5.4.1. APPLICATION
        • 4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.4.5. KEY CONCLUSIONS
  • 4.3. INJECTABLE DRUG DELIVERYMARKET BY THERAPEUTIC APPLICATION
    • 4.3.1. MARKET DEFINITION AND SCOPE
    • 4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.3.4. OPPORTUNITY MATRIX
    • 4.3.5. MARKET SEGMENTATION
      • 4.3.5.1. GLOBAL AUTO IMMUNE DISEASES MARKET
        • 4.3.5.1.1. APPLICATION
        • 4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.1.5. KEY CONCLUSIONS
      • 4.3.5.2. GLOBAL HORMONAL DISORDERS MARKET
        • 4.3.5.2.1. APPLICATION
        • 4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.2.5. KEY CONCLUSIONS
      • 4.3.5.3. GLOBAL ONCOLOGY MARKET
        • 4.3.5.3.1. APPLICATION
        • 4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.3.5. KEY CONCLUSIONS
      • 4.3.5.4. GLOBAL ORPHAN DISEASES MARKET
        • 4.3.5.4.1. APPLICATION
        • 4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.4.5. KEY CONCLUSIONS
      • 4.3.5.5. GLOBAL OTHERS MARKET
        • 4.3.5.5.1. APPLICATION
        • 4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.5.5. KEY CONCLUSIONS
  • 4.4. INJECTABLE DRUG DELIVERYMARKET BY USAGE PATTERN
    • 4.4.1. MARKET DEFINITION AND SCOPE
    • 4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.4.4. OPPORTUNITY MATRIX
    • 4.4.5. MARKET SEGMENTATION
      • 4.4.5.1. GLOBAL CURATIVE CARE MARKET
        • 4.4.5.1.1. APPLICATION
        • 4.4.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.4.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.4.5.1.5. KEY CONCLUSIONS
      • 4.4.5.2. GLOBAL IMMUNIZATION MARKET
        • 4.4.5.2.1. APPLICATION
        • 4.4.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.4.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.4.5.2.5. KEY CONCLUSIONS
      • 4.4.5.3. GLOBAL OTHERS MARKET
        • 4.4.5.3.1. APPLICATION
        • 4.4.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.4.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.4.5.3.5. KEY CONCLUSIONS
  • 4.5. INJECTABLE DRUG DELIVERYMARKET BY END USER
    • 4.5.1. MARKET DEFINITION AND SCOPE
    • 4.5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.5.4. OPPORTUNITY MATRIX
    • 4.5.5. MARKET SEGMENTATION
      • 4.5.5.1. GLOBAL HOSPITALS MARKET
        • 4.5.5.1.1. APPLICATION
        • 4.5.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.5.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.5.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.5.5.1.5. KEY CONCLUSIONS
      • 4.5.5.2. GLOBAL HOMECARE MARKET
        • 4.5.5.2.1. APPLICATION
        • 4.5.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.5.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.5.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.5.5.2.5. KEY CONCLUSIONS
      • 4.5.5.3. GLOBAL OTHERS (RESEARCH INSTITUTES, CLINICAL, DIAGNOSTIC LABORATORIES) MARKET
        • 4.5.5.3.1. APPLICATION
        • 4.5.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.5.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.5.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.5.5.3.5. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF MERGERS AND ACQUISITION
    • 5.1.2. LIST OF JOINT VENTURES
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIPS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GLOBAL INJECTABLE DRUG DELIVERYMARKET BY REGION 2014-2023 ($ MILLION)
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. FRANCE
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. GERMANY
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. SPAIN
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. REST OF EUROPE
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. AUSTRALIA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. REST OF ASIA PACIFIC
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

  • 7.1. BECTON DICKINSON AND COMPANY (U.S.)
    • 7.1.1. OVERVIEW
    • 7.1.2. PRODUCT PORTFOLIO
    • 7.1.3. KEY INNOVATION SECTOR
    • 7.1.4. STRATEGIC INITIATIVES
    • 7.1.5. SCOT ANALYSIS
    • 7.1.6. STRATEGIC ANALYSIS
  • 7.2. BAXTER INTERNATIONAL (U.S.)
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. KEY INNOVATION SECTOR
    • 7.2.4. STRATEGIC INITIATIVES
    • 7.2.5. SCOT ANALYSIS
    • 7.2.6. STRATEGIC ANALYSIS
  • 7.3. PFIZER (U.S.)
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. KEY INNOVATION SECTOR
    • 7.3.4. STRATEGIC INITIATIVES
    • 7.3.5. SCOT ANALYSIS
    • 7.3.6. STRATEGIC ANALYSIS
  • 7.4. GERRESHEIMER AG (GERMANY)
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. KEY INNOVATION SECTOR
    • 7.4.4. STRATEGIC INITIATIVES
    • 7.4.5. SCOT ANALYSIS
    • 7.4.6. STRATEGIC ANALYSIS
  • 7.5. SCHOTT AG (GERMANY)
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. KEY INNOVATION SECTOR
    • 7.5.4. STRATEGIC INITIATIVES
    • 7.5.5. SCOT ANALYSIS
    • 7.5.6. STRATEGIC ANALYSIS
  • 7.6. ELI LILLY AND COMPANY (U.S.)
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. KEY INNOVATION SECTOR
    • 7.6.4. STRATEGIC INITIATIVES
    • 7.6.5. SCOT ANALYSIS
    • 7.6.6. STRATEGIC ANALYSIS
  • 7.7. TERUMO CORPORATION (U.S.)
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. KEY INNOVATION SECTOR
    • 7.7.4. STRATEGIC INITIATIVES
    • 7.7.5. SCOT ANALYSIS
    • 7.7.6. STRATEGIC ANALYSIS
  • 7.8. ANTARES PHARMA INC. (U.S.)
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. KEY INNOVATION SECTOR
    • 7.8.4. STRATEGIC INITIATIVES
    • 7.8.5. SCOT ANALYSIS
    • 7.8.6. STRATEGIC ANALYSIS
  • 7.9. HOSPIRA INC. (U.S.)
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. KEY INNOVATION SECTOR
    • 7.9.4. STRATEGIC INITIATIVES
    • 7.9.5. SCOT ANALYSIS
    • 7.9.6. STRATEGIC ANALYSIS
  • 7.10. NONO NORDISK (DENMARK)
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. KEY INNOVATION SECTOR
    • 7.10.4. STRATEGIC INITIATIVES
    • 7.10.5. SCOT ANALYSIS
    • 7.10.6. STRATEGIC ANALYSIS
  • 7.11. SANOFI SA (FRANCE)
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. KEY INNOVATION SECTOR
    • 7.11.4. STRATEGIC INITIATIVES
    • 7.11.5. SCOT ANALYSIS
    • 7.11.6. STRATEGIC ANALYSIS
  • 7.12. SCANDINAVIAN HEALTH LTD. (TAIWAN)
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. KEY INNOVATION SECTOR
    • 7.12.4. STRATEGIC INITIATIVES
    • 7.12.5. SCOT ANALYSIS
    • 7.12.6. STRATEGIC ANALYSIS
  • 7.13. TERUMO CORPORATION (JAPAN)
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. KEY INNOVATION SECTOR
    • 7.13.4. STRATEGIC INITIATIVES
    • 7.13.5. SCOT ANALYSIS
    • 7.13.6. STRATEGIC ANALYSIS
  • 7.14. UNILIFE CORPORATION (U.S.)
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. KEY INNOVATION SECTOR
    • 7.14.4. STRATEGIC INITIATIVES
    • 7.14.5. SCOT ANALYSIS
    • 7.14.6. STRATEGIC ANALYSIS
  • 7.15. ZOGENIX INC. (U.S.)
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. KEY INNOVATION SECTOR
    • 7.15.4. STRATEGIC INITIATIVES
    • 7.15.5. SCOT ANALYSIS
    • 7.15.6. STRATEGIC ANALYSIS

LIST OF TABLES

  • Table 1. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY TYPE 2014-2023 ($ MILLION)
  • Table 2. GLOBAL DEVICES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 3. GLOBAL FORMULATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 4. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY FORMULATION2014-2023 ($ MILLION)
  • Table 5. GLOBAL AMPULES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 6. GLOBAL BOTTLES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 7. GLOBAL CARTRIDGES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 8. GLOBAL VIALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 9. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY THERAPEUTIC APPLICATION 2014-2023 ($ MILLION)
  • Table 10. GLOBAL AUTO IMMUNE DISEASES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 11. GLOBAL HORMONAL DISORDERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 12. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 13. GLOBAL ORPHAN DISEASES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 14. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 15. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY USAGE PATTERN2014-2023 ($ MILLION)
  • Table 16. GLOBAL CURATIVE CARE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 17. GLOBAL IMMUNIZATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 18. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 19. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY END USER 2014-2023 ($ MILLION)
  • Table 20. GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 21. GLOBAL HOMECARE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 22. GLOBAL OTHERS (RESEARCH INSTITUTES, CLINICAL, DIAGNOSTIC LABORATORIES) MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 23. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Table 24. EUROPE INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Table 25. ASIA PACIFIC INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Table 26. REST OF THE WORLD INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

  • Figure 1. GLOBAL INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 2. GLOBAL DEVICES MARKET 2014-2023 ($ MILLION)
  • Figure 3. GLOBAL FORMULATIONS MARKET 2014-2023 ($ MILLION)
  • Figure 4. GLOBAL AMPULES MARKET 2014-2023 ($ MILLION)
  • Figure 5. GLOBAL BOTTLES MARKET 2014-2023 ($ MILLION)
  • Figure 6. GLOBAL CARTRIDGES MARKET 2014-2023 ($ MILLION)
  • Figure 7. GLOBAL VIALS MARKET 2014-2023 ($ MILLION)
  • Figure 8. GLOBAL AUTO IMMUNE DISEASES MARKET 2014-2023 ($ MILLION)
  • Figure 9. GLOBAL HORMONAL DISORDERS MARKET 2014-2023 ($ MILLION)
  • Figure 10. GLOBAL ONCOLOGY MARKET 2014-2023 ($ MILLION)
  • Figure 11. GLOBAL ORPHAN DISEASES MARKET 2014-2023 ($ MILLION)
  • Figure 12. GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
  • Figure 13. GLOBAL CURATIVE CARE MARKET 2014-2023 ($ MILLION)
  • Figure 14. GLOBAL IMMUNIZATION MARKET 2014-2023 ($ MILLION)
  • Figure 15. GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
  • Figure 16. GLOBAL HOSPITALS MARKET 2014-2023 ($ MILLION)
  • Figure 17. GLOBAL HOMECARE MARKET 2014-2023 ($ MILLION)
  • Figure 18. GLOBAL OTHERS (RESEARCH INSTITUTES, CLINICAL, DIAGNOSTIC LABORATORIES) MARKET 2014-2023 ($ MILLION)
  • Figure 19. UNITED STATES (U.S.) INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 20. CANADA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 21. UNITED KINGDOM (UK) INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 22. FRANCE INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 23. GERMANY INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 24. SPAIN INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 25. ROE INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 26. INDIA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 27. CHINA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 28. JAPAN INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 29. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 30. ROAPAC INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 31. LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 32. MENA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
Back to Top